Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors

Download All
In this online program based on a series of CLL Webinars, experts discuss evidence-based best practices in using BTK inhibitors to treat patients with CLL. Watch the on-demand Webcast and download the slides now.
Danielle Brander, MD
Nicole Lamanna, MD
Jeff P. Sharman, MD

Podcasts

Listen to CLL experts Jeff Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Released: September 17, 2020

Hear from experts Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, as they answer audience questions from the second in a series of live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Released: September 16, 2020

Hear from experts Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, as they answer audience questions from the third in a series of live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Released: September 17, 2020

On-Demand Webcast

Gain expert insight with this on-demand Webcast on the latest treatment strategies with BTK inhibitors for improving outcomes in patients with CLL.

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: September 16, 2020 Expired: September 15, 2021

ClinicalThought

Why testing for TP53, del(17q), and IGHV status critical for treatment selection and outcome optimization. Here’s my take.

Danielle Brander, MD Released: September 22, 2020

The implications of minimal residual disease status on treatment of CLL is evolving. Here’s my take on what you should know now.

Danielle Brander, MD Released: September 29, 2020

Get the latest information on how investigational noncovalent BTK inhibitors, such as LOXO-305 and ARQ 531, may help treat patients with CLL and resistance to currently available BTK inhibitors.

Jeff P. Sharman, MD Released: September 25, 2020

Downloadable Slidesets

Download this short slideset of key takeaways from a live CCO Webinar focused on the optimal use of BTK inhibitors in patients with CLL.

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Released: July 10, 2020

Downloadable slides with expert analysis of the BCR pathway and BTK inhibitors in CLL.

Jeff P. Sharman, MD Released: June 10, 2020

Downloadable slides with expert analysis of potential future applications for BTK inhibitors.

Jeff P. Sharman, MD Released: June 10, 2020

Downloadable slides with expert analysis of the use of BTK inhibitors for patients with treatment-naive CLL.

Danielle Brander, MD Released: June 10, 2020

Downloadable slides with expert analysis of the optimal use of BTK inhibitors in patients with relapsed/refractory CLL.

Nicole Lamanna, MD Released: June 10, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue